The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program

被引：2
|
作者：
Silberstein, S. [1 ]
Dodick, D. W. [2 ]
DeGryse, R. E. [3 ]
Lipton, R. [4 ]
Turkel, C. C. [3 ]
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[2] Mayo Clin Arizona, Phoenix, AZ USA
[3] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
[4] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2013年 / 14卷
关键词：
Migraine; Treatment Cycle; Chronic Migraine; Migraine Patient; Responder Rate;
D O I：
10.1186/1129-2377-14-S1-P200
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Percent of Chronic Migraine Patients Who Responded to OnabotulinumtoxinA Treatment Per Treatment Cycle in the PREEMPT Clinical Program
    Silberstein, Stephen
    Dodick, David
    DeGryse, Ronald
    Lipton, Richard
    Turkel, Catherine
    NEUROLOGY, 2012, 78
  • [2] The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program
    S Silberstein
    DW Dodick
    RE DeGryse
    R Lipton
    CC Turkel
    The Journal of Headache and Pain, 2013, 14
  • [3] Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
    Silberstein, Stephen D.
    Dodick, David W.
    Aurora, Sheena K.
    Diener, Hans-Christoph
    DeGryse, Ronald E.
    Lipton, Richard B.
    Turkel, Catherine C.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (09): : 996 - 1001
  • [4] OnabotulinumtoxinA for Chronic Migraine: Efficacy and Tolerability in Patients Who Received All 5 Treatment Cycles in the PREEMPT Clinical Program
    Aurora, S. K.
    Dodick, D. W.
    DeGryse, R. E.
    Turkel, C. C.
    HEADACHE, 2011, 51 : 61 - 61
  • [5] OnabotulinumtoxinA for Chronic Migraine: Safety and Tolerability of the Effective Treatment Paradigm in the PREEMPT Clinical Program
    Aurora, S. K.
    Dodick, D. W.
    Blumenfeld, A.
    DeGryse, R. E.
    Turkel, C. C.
    HEADACHE, 2010, 50 : S14 - S15
  • [6] OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
    Aurora, S. K.
    Dodick, D. W.
    Diener, H. -C.
    DeGryse, R. E.
    Turkel, C. C.
    Lipton, R. B.
    Silberstein, S. D.
    ACTA NEUROLOGICA SCANDINAVICA, 2014, 129 (01): : 61 - 70
  • [7] OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program
    Aurora, Sheena K.
    Winner, Paul
    Freeman, Marshall C.
    Spierings, Egilius L.
    Heiring, Jessica O.
    DeGryse, Ronald E.
    VanDenburgh, Amanda M.
    Nolan, Marissa E.
    Turkel, Catherine C.
    HEADACHE, 2011, 51 (09): : 1358 - 1373
  • [8] OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm
    Isabel Pedraza, Maria
    de la Cruz, Carolina
    Ruiz, Marina
    Lopez-Mesonero, Luis
    Martinez, Elena
    de Lera, Mercedes
    Luis Guerrero, Angel
    SPRINGERPLUS, 2015, 4
  • [9] OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
    Aurora, S. K.
    Dodick, D. W.
    DeGryse, R. E.
    Turkel, C. C.
    JOURNAL OF HEADACHE AND PAIN, 2013, 14
  • [10] OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
    SK Aurora
    DW Dodick
    RE DeGryse
    CC Turkel
    The Journal of Headache and Pain, 2013, 14
12345